Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Inclusion Criteria:

* Younger than 22 years of age.
* Histologic verification of solid tumor malignancy at original diagnosis.
* Has disease considered refractory to conventional therapy or no conventional therapy exists.
* Adequate performance status, bone marrow, liver and kidney function.
* Patients must not have had any previous allergic reactions to penicillin or cephalosporins

Exclusion Criteria:

* Known severe hypersensitivity to ZD1839 or any of the excipients of this product
* Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's Wort, and CYP3A4 inhibitors
* Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.
* Incomplete healing from previous oncologic or other major surgery
* Pregnant or breast-feeding
* Patients who have an uncontrolled infection
* Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).
* As judged by the investigator, any evidence of uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
* Evidence of any other significant clinical disorder or laboratory finding that makes is undesirable for the subject to participate in the trial.